article thumbnail

Exploring Melbourne’s booming life sciences sector

Pharmaceutical Technology

Australia is fast becoming the place to be for innovative life sciences companies, as proved by Melbourne’s latest FDI wins from the likes of BioNTech and Moderna.

article thumbnail

Digital dilemma in UK’s life sciences job market

Pharmaceutical Technology

In this issue: Digital jobs in UK life sciences, generative AI changes drug discovery, and how robotics is impacting gene therapy manufacturing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How life sciences benefits from broader healthcare transformation

Bio Pharma Dive

Digital transformation has much to offer life sciences as well as healthcare — and the synergies between the two can further optimize the power of digital health, clinical trials and patient outcomes.

article thumbnail

UK life science industry optimistically embraces Labour victory

Pharmaceutical Technology

The UK life science industry is crossing its fingers as a Labour government takes the reigns following 14 years of Conservative rule.

article thumbnail

Forbion raises $1.47bn for two life sciences-focused funds

Pharmaceutical Technology

European life sciences venture capital firm Forbion has raised €1.35bn ($1.47bn) across its two new funds. The Forbion Growth Opportunities Fund II provides support to the expansion of late-stage life sciences companies. The latest fundraising brings the total funds managed by the company to €3bn ($3.28bn).

article thumbnail

FABA’s life sciences innovation cluster works on global partnerships to propel novel biologics & diagnostics

AuroBlog - Aurous Healthcare Clinical Trials blog

Federation of Asian Biotech Associations’ (FABA) Life Sciences Innovation Cluster is now working to strengthen the global partnerships to propel an ecosystem for novel biologics and diagnostics.

article thumbnail

Podcast #2: Doing Digital Deals in Life Sciences | Information Governance

Pharmaceutical Technology

In this series, life sciences industry M&A veteran John Easton will discuss how digital deals differ from traditional life science deals